Non-Current Assets
Indefinite-Lived Research and Development Assets
Capital One Financial Indefinite-Lived Research and Development Assets remained flat by 0.0% to $4.98B in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2024
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
Metric ID:
indefinite_lived_rd_assetsHistorical Data
5 periods
| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $8.00M | $5.38B | $4.98B | $4.98B | $4.98B |
| QoQ Change | — | >999% | -7.4% | +0.0% | +0.0% |
| YoY Change | — | — | — | >999% | — |
Range$8.00M – $5.38B
CAGR>999%
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak2 quarters growth
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Capital One Financial's indefinite-lived research and development assets?
- Capital One Financial (COF) reported indefinite-lived research and development assets of $4.98B in Q1 2026.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.